Antengene Presented First Preclinical Data at EULAR 2026 Showing ATG-207 Promotes Regulatory T Cell Induction and Immune Tolerance
08-06-2026 02:00 via prnewswire.com

Antengene Presented First Preclinical Data at EULAR 2026 Showing ATG-207 Promotes Regulatory T Cell Induction and Immune Tolerance

SHANGHAI and HONG KONG, June 7, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for...
Read more »

PR Public relations news



Uhale Adopts Quokka's Q-mast to Strengthen Application Security Testing
New Report "Early Bird" Maps Tech Investing for Asian Family Offices
New Report "Early Bird" Maps Tech Investing for Asian Family Offices
GIGABYTE impulsa las tecnologías de monitores gaming con imágenes optimizadas por IA y protección OLED automática
GIGABYTE impulsa las tecnologías de monitores gaming con imágenes optimizadas por IA y protección OLED automática
GIGABYTE fait progresser les technologies des écrans gaming à l'aide de visuels optimisés par IA et d'une protection automatique de l'OLED
GIGABYTE fait progresser les technologies des écrans gaming à l'aide de visuels optimisés par IA et d'une protection automatique de l'OLED
GIGABYTE Advances Gaming Monitor Technologies with AI-optimized Visuals and Automatic OLED Protection
GIGABYTE Advances Gaming Monitor Technologies with AI-optimized Visuals and Automatic OLED Protection
Anamana Incubator Targets Culturally Native Creators to Diversify Homogenized Micro-Drama Market
Anamana Incubator Targets Culturally Native Creators to Diversify Homogenized Micro-Drama Market
Ascletis Reinforces Its Differentiated Obesity Portfolio at American Diabetes Association (ADA) 2026 Scientific Sessions, Showcasing ASC30 Clinical Data and Exciting Preclinical Findings from ASC37 and ASC39
Ascletis Reinforces Its Differentiated Obesity Portfolio at American Diabetes Association (ADA) 2026 Scientific Sessions, Showcasing ASC30 Clinical Data and Exciting Preclinical Findings from ASC37 and ASC39
OriCell's GPC3 CAR-T Receives NMPA Clearance for Confirmatory Phase II Trial in Late-Line Advanced Hepatocellular Carcinoma
UPST Deadline: UPST Investors Have Opportunity to Lead Upstart Holdings, Inc. Securities Fraud Lawsuit
UPST Deadline: UPST Investors Have Opportunity to Lead Upstart Holdings, Inc. Securities Fraud Lawsuit
Sportradar Group AG (SRAD) Investors: July 17, 2026, Deadline in Securities Fraud Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP
Sportradar Group AG (SRAD) Investors: July 17, 2026, Deadline in Securities Fraud Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP
VolitionRx Announces Pricing of $4.6 Million Public Offering
Once-Weekly CagriSema (Amylin-Semaglutide) Combination Injection More Effective than Standalone Medications
Once-Weekly CagriSema (Amylin-Semaglutide) Combination Injection More Effective than Standalone Medications
Novo Nordisk's CagriSema 2.4 mg / 2.4 mg demonstrated significant reduction in HbA1c and weight across multiple studies in the REIMAGINE program presented at ADA 2026
Novo Nordisk's CagriSema 2.4 mg / 2.4 mg demonstrated significant reduction in HbA1c and weight across multiple studies in the REIMAGINE program presented at ADA 2026
Lipid-Lowering Medications Demonstrate Cardiometabolic Benefits in Populations with High-Risk Diabetes
Lipid-Lowering Medications Demonstrate Cardiometabolic Benefits in Populations with High-Risk Diabetes
Desktop versie